NCT00993876.
Methods | Randomised, open‐label trial. |
Participants | Patients with MDD according to DSM‐IV criteria. |
Interventions | Citalopram: 20‐30 mg/day. Reboxetine: 4‐8 mg/day. |
Outcomes | Cognitive performance with respect to cognitive flexibility, memory and attention. |
Notes |